Easywell Biomedicals (ROCO:1799) Beginning Cash Position: NT$323.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:1799 Easywell Biomedicals Inc ROCO:1799
59 GF Score
Price NT$29.90
GF Value NT$88.61
Valuation Significantly Undervalued
View Full Analysis

What is Easywell Biomedicals Beginning Cash Position?

Easywell Biomedicals ROCO:1799 -0.99% 59 Beginning Cash Position is NT$323.3 Mil as of Jun. 2026. GuruFocus rates ROCO:1799 with a GF Score™ of 59/100 and a GF Value™ of NT$88.61 (Significantly Undervalued).

Easywell Biomedicals's Beginning Cash Position for the quarter that ended in Jun. 2026 was NT$323.3 Mil.

Easywell Biomedicals's quarterly Beginning Cash Position increased from Dec. 2025 (NT$230.7 Mil) to Mar. 2026 (NT$281.1 Mil) and increased from Mar. 2026 (NT$281.1 Mil) to Jun. 2026 (NT$323.3 Mil).

Easywell Biomedicals's annual Beginning Cash Position increased from Dec. 2023 (NT$159.0 Mil) to Dec. 2024 (NT$262.9 Mil) and increased from Dec. 2024 (NT$262.9 Mil) to Dec. 2025 (NT$325.7 Mil).

Easywell Biomedicals Beginning Cash Position Related Terms

Easywell Biomedicals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Easywell Biomedicals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Easywell Biomedicals Beginning Cash Position Chart

Easywell Biomedicals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 144.89 153.03 159.03 262.91 325.67

Easywell Biomedicals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 389.95 233.94 230.74 281.06 323.29
ROCO:1799
59GF Score
Easywell Biomedicals Inc ROCO:1799
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Easywell Biomedicals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$323.3 Mil mean?
Easywell Biomedicals (ROCO:1799) has a Beginning Cash Position of NT$323.3 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Easywell Biomedicals and its competitors.
Is Easywell Biomedicals' Beginning Cash Position too high?
Easywell Biomedicals' current Beginning Cash Position is NT$323.3 Mil. Overall, Easywell Biomedicals has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easywell Biomedicals' Beginning Cash Position compare to ZTS?
Easywell Biomedicals' Beginning Cash Position of NT$323.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Easywell Biomedicals and its competitors. Easywell Biomedicals's current Beginning Cash Position is NT$323.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easywell Biomedicals stock overvalued right now?
Based on GuruFocus' analysis, Easywell Biomedicals (ROCO:1799) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$88.61, compared to a current price of NT$29.90 — trading 66.3% below its estimated fair value. The current Beginning Cash Position is NT$323.3 Mil. Easywell Biomedicals' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Easywell Biomedicals (ROCO:1799), the current Beginning Cash Position is NT$323.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?

Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued. The current stock price of NT$29.90 is trading 66.3% below its estimated GF Value™ of NT$88.61. GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.

Key valuation signals for ROCO:1799:

  • Beginning Cash Position: NT$323.3 Mil
  • GF Value™: NT$88.61 vs. price of NT$29.90 (66.3% below fair value)
  • GF Score™: 59/100

No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Easywell Biomedicals Business Description

Address No.10, Yanfa 2nd Road, Hsinchu Science Park, 1st floor, Hsinchu, TWN, 30076
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
59GF Score

Get the complete analysis for ROCO:1799

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$29.90
Price
NT$88.61
GF Value